COEP vs. SNTI, IKT, BCDA, ONVO, NSTGQ, GENE, SRNE, TTNP, CELZ, and PMCB
Should you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Senti Biosciences (SNTI), Inhibikase Therapeutics (IKT), BioCardia (BCDA), Organovo (ONVO), NanoString Technologies (NSTGQ), Genetic Technologies (GENE), Sorrento Therapeutics (SRNE), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), and PharmaCyte Biotech (PMCB). These companies are all part of the "biological products, except diagnostic" industry.
Coeptis Therapeutics (NASDAQ:COEP) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings.
Coeptis Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Coeptis Therapeutics has a net margin of 0.00% compared to Senti Biosciences' net margin of -2,692.82%. Senti Biosciences' return on equity of -74.59% beat Coeptis Therapeutics' return on equity.
Coeptis Therapeutics has a beta of -0.89, suggesting that its stock price is 189% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500.
Coeptis Therapeutics received 2 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 100.00% of users gave Coeptis Therapeutics an outperform vote while only 33.33% of users gave Senti Biosciences an outperform vote.
13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 12.5% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Coeptis Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 796.06%. Senti Biosciences has a consensus target price of $6.00, indicating a potential upside of 1,968.97%. Given Senti Biosciences' higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Coeptis Therapeutics.
In the previous week, Coeptis Therapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 2 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.84 beat Coeptis Therapeutics' score of 0.10 indicating that Senti Biosciences is being referred to more favorably in the news media.
Summary
Coeptis Therapeutics and Senti Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Coeptis Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coeptis Therapeutics Competitors List
Related Companies and Tools
